1. Introduction {#sec1}
===============

Gastric cancer (GC) is the most common gastrointestinal malignancy and the third leading cause of cancer-related death worldwide \[[@B1]\]. Although radical gastrectomy has been regarded as an effective treatment, prognosis for GC patients remains poor, with a 5-year overall survival (OS) rate of only 27.4% in China \[[@B2]\]. GC patients have different outcomes even when they are diagnosed at the same clinical stage and receiving the same treatment \[[@B3]\], which suggests that the host characteristics, specifically the genetic factors, play crucial roles in GC prognosis. Single nucleotide polymorphisms (SNPs) are the most common genetic variations and reportedly influence the patients\' clinical outcomes \[[@B4]--[@B6]\].

DNA methylation, which is established and maintained by DNA methyltransferases (DNMTs), is the major direct modification of eukaryotic DNA and is known to have profound effects on the regulation of gene expression \[[@B7]--[@B10]\]. DNMT1 is the primary enzyme that maintains the level of DNA methylation \[[@B11]\]. Aberrant expression of DNMT1 is correlated with progression and prognosis of various cancers, such as lung cancer \[[@B12]\], hepatocellular carcinoma \[[@B13]\], pancreatic cancer \[[@B14]\], and bladder cancer \[[@B15]\]. In GC, overexpression of DNMT1 correlates with worse differentiation, advanced stage, and increased risk of death \[[@B16]--[@B18]\]. Meanwhile, inhibition or blockade of DNMT1 can arrest cell cycle, increase cell apoptosis, decrease invasion, and enhance treatment sensitivity \[[@B15], [@B16], [@B19]\].

Previous studies have reported that SNPs of*DNMT1* gene are associated with susceptibility to cancers such as ovarian cancer \[[@B20]\] and breast cancer \[[@B21]\]. In GC, though Khatami et al. found no association in an Iranian population \[[@B22]\], Yang et al. observed a 45% increased risk in individuals bearing rs16999593 C allele in Southern Chinese population \[[@B23]\]. Our previous study showed that rs10420321 GG or rs8111085 CC genotype was associated with lower risk of*Helicobacter pylori* infection but higher risk of gastric atrophy \[[@B24]\].

Given the role of DNMT1 in cancer progression and prognosis, we hypothesized that SNPs of*DNMT1* may have prognostic value of cancer. As far as we know, there was no study on it. The aim of our study was to explore the role of SNPs of*DNMT1* in the prognosis of gastric cancer \[[@B23]\].

2. Material and Methods {#sec2}
=======================

2.1. Subject Selection {#sec2.1}
----------------------

Subjects of the study were described elsewhere \[[@B24], [@B25]\]. From August 2008 to December 2010, a total of 447 GC patients who underwent tumorectomy in the Department of Gastric and Colorectal Surgery of the First Hospital of Jilin University were recruited in this study. All of them were histologically diagnosed with gastric cancer and none of them received chemotherapy or radiotherapy before surgery. All patients were Han descent from the area of Changchun. Clinical and pathological data were collected including age, gender, tumor size, pathological type, differentiation, depth of invasion, lymph metastasis, distant metastasis, lymph-vascular invasion, and therapy. The clinical stage of gastric cancer was evaluated by the TNM classification according to American Joint Committee on Cancer (AJCC) in 2010, the seventh edition \[[@B26]\]. Written informed consent was obtained from each patient before sample collection. This study was approved by the ethics committee of the First Hospital of Jilin University.

The follow-up of patients was performed by telephone calls three months, six months, and one year after the tumorectomy and every one year thereafter until death or being lost to follow-up. The following data were recorded during each follow-up: the health status of patients, therapy after operation, and date of death if the patients died. About one-third of the patients received chemotherapy after surgery. The chemotherapy mainly consisted of three regimens: FOLFOX-4 regimen (combination with 5-fluorouracil, leucovorin, and oxaliplatin); XELOX regimen (capecitabine and oxaliplatin); and other chemotherapies such as capecitabine or 5-fluorouracil alone. A patient would be considered to have postoperative chemotherapy only if they received the therapy for at least 3 cycles.

2.2. Selection of Tagging SNPs {#sec2.2}
------------------------------

The detailed description of tagging SNPs selection was depicted in our previous work \[[@B24]\]. Briefly, tagging SNPs were selected from the Chinese Han data (CHB) in the HapMap Project (06-02-2009 HapMap) using the SNP browser Software v4.0 to capture SNPs with minimum minor allele frequency (MAF) \> 0.05 and pairwise *r* ^2^ ≥ 0.8 \[[@B27]\]. There were 27 SNPs with MAF \> 0.05 in*DNMT1* gene region in the Chinese on HapMap. Three of them lie in the coding regions, including two nonsynonymous SNPs of rs16999593 (His97Arg) in exon 4 and rs2228612 (Ile327Val) in exon 12 and one synonymous SNP rs2228611 in exon 17. The remaining 24 SNPs reside in introns of*DNMT1*. Five linkage disequilibrium (LD) blocks were identified. The 3 SNPs in coding region could tag the blocks they belonged to (*D*′ = 1 and *r* ^2^ = 0.8) and were selected. Finally, five SNPs, rs10420321, rs16999593, rs2228612, rs2228611, and rs2288349, were selected as tagging SNPs for further study.

2.3. Genotyping {#sec2.3}
---------------

Blood samples of each subject were collected in EDTA tubes and stored in −80°C until DNA extraction. Genomic DNA was extracted using commercial kits following the protocol provided by the manufacturer (AxyPrep Blood Genomic DNA Miniprep kit, Axygen Biosciences, USA). Genotypes of each SNP were determined by TaqMan SNP genotyping assays in 384-well plates (Applied Biosystems, USA) and the detailed process of polymerase chain reaction (PCR) was described elsewhere \[[@B24]\]. The PCR products were read on ABI PRISM 7900 Sequence Detector in the end-point mode and genotypes were identified using the Allelic Discrimination Sequence Detector Software V2.3. Ten randomly selected samples were genotyped twice in all SNPs to verify genotyping and sample-handling accuracy and the concordance rate was 100%. The call rates for rs10420321, rs16999593, rs2228612, rs2228611, and rs2288349 were 91.7%, 100%, 100%, 99.5%, and 99.3%, respectively.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Overall survival was defined as the time from the date of surgery to the date of death (if the patients were dead) or to the date of final follow-up (if the patients were alive) or to the date of the last follow-up (if the patients were lost to follow-up). Survival time would be right-censored in case that the patients were alive, were lost to follow-up, or died of causes other than GC. Patients would be excluded from survival analysis if they were lost to follow-up at the first interview or they died of postoperative complications within 30 days such as uncontrollable bleeding during perioperative period.

Survival curves of the GC patients within each SNP were plotted by Kaplan-Meier method and compared by log-rank test. The median survival time was estimated by the Kaplan-Meier method. If median OS could not be calculated, mean OS would be used instead. Hazard ratios (HRs) with their 95% confidence intervals (CIs) were calculated by the Cox proportional hazards model after adjusting for age (scale variable), sex (nominal variable), clinical stage (scale variable), and postoperational chemotherapy (nominal variable). Stepwise Cox regression analysis was conducted to determine independent predictive factors of prognosis, with a significance level of *P* \< 0.05 for entering and *P* \> 0.05 for removing the variables. All analyses were performed using SPSS18.0 Software (SPSS Inc., USA). Two-tailed *P* values \< 0.05 were considered to be statistically significant.

3. Results {#sec3}
==========

3.1. Characteristics of Patients {#sec3.1}
--------------------------------

A total of 447 patients with histologically confirmed GC were enrolled in the study. Twelve patients (2.7%) could not be connected any more after they left the hospital and follow-up information was available for 435 patients (97.3%) until March 2016. Thirteen patients (2.9%) died of postoperative complications. These 25 cases (12 + 13 = 25, 5.6%) were excluded from the analysis of effects of SNPs on survival. The remaining 422 patients were enrolled in further analysis. During the follow-up period, 197 (46.2%) patients died of gastric cancer, 19 (3.3%) died of other causes such as cerebral hemorrhage, 17 (2.4%) were lost to follow-up, and 189 (48.1%) were alive. The duration of follow-up ranged from 1.1 to 85.0 months with a median of 59.9 months (95% CI: 59.4--60.5 months).

The baseline characteristics and clinical features of these patients are detailed in [Table 1](#tab1){ref-type="table"}. Of these patients, 72.3% were male gender, 87.4% were tubular adenoma type, 62.9% were poorly differentiated, 43.1% were at advanced stage (TNM III or IV), 96.4% received radical gastrectomy, and 32.7% received postoperational chemotherapy. Survival analysis shows that patients in male gender, with tumor size \> 5 cm, with deeper invasion, with presence of lymph node metastasis or distant metastasis, with advanced TNM stage, positive for lymph-vascular or neural invasion, and receiving palliative surgery only had shorter postoperational survival compared to patients without (log-rank *P* \< 0.05, [Table 1](#tab1){ref-type="table"}).

3.2. Association between Genotypes and Survival of Gastric Cancer {#sec3.2}
-----------------------------------------------------------------

As reported by our previous work \[[@B24]\], no association was found between the SNPs and pathological type, tumor differentiation, TNM stage, and lymph-vascular or neural invasion ([Table 2](#tab2){ref-type="table"}).

Survival curves within each SNP of*DNMT1* were plotted and compared using the codominant, dominant, and recessive model ([Table 3](#tab3){ref-type="table"}). More than half of patients bearing the GG genotype of rs2228611 (117/221 = 52.9%) died of GC until the final follow-up, whereas only 39.7% of patients with the GA or AA genotype died (*P* = 0.007). Comparing to patients carrying the GG genotype of rs2228611, patients with GA or AA genotype had reduced risk of death after surgery (GA: HR 0.66, 95% CI 0.48--0.89; AA: HR 0.81, 95% CI 0.46--1.44). Result from the dominant model combining patients with GA or AA genotype showed that the A allele bearers of rs2228611 had 32% lower risk of death comparing to the GG carriers (HR 0.68, 95% CI 0.51--0.90, log-rank *P* = 0.007, [Figure 1](#fig1){ref-type="fig"}). Further subgroup analysis in patients receiving radical gastrectomy showed similar correlation where A allele reduced the death risk by 35% (HR 0.65, 95% CI 0.48--0.88, log-rank *P* = 0.005; adjusting for age, sex, TNM stage, and chemotherapy).

Other four SNPs, rs10420321, rs16999593, rs2228612, and rs2288349, were not associated with the overall survival of GC ([Table 3](#tab3){ref-type="table"}). Further haplotype analysis did not show associations between the haplotype and survival in GC ([Table 3](#tab3){ref-type="table"}).

3.3. Stratified Analysis between Genotypes and Survival {#sec3.3}
-------------------------------------------------------

We further performed the stratified analysis for rs2228611 to investigate if this SNP on survival was modified by some important clinicopathological factors. As presented in [Figure 2](#fig2){ref-type="fig"}, patients carrying GA/AA variant genotypes had a lower death risk than those with the GG genotype. The protective effect was more pronounced among patients with relatively early clinical stage (HR 0.53, 95% CI: 0.31--0.91; *P* = 0.021).

3.4. Stepwise Cox Regression Model for GC Survival {#sec3.4}
--------------------------------------------------

Further multivariate Cox regression analysis showed that rs2228611 was an independent predictive factor for GC (GA/AA versus GG, HR 0.67, 95% CI 0.49--0.91, *P* = 0.010). Other factors, male gender (HR 1.80, 95% CI 1.22--2.67; *P* = 0.003), advanced TNM stage (HR 4.76, 95% CI: 3.28--6.90; *P* \< 0.001), tumor size ≥ 5 cm (HR 1.56, 95% CI: 1.13--2.16; *P* = 0.007), and lymph-vascular invasion (HR 1.52, 95% CI: 1.08--2.14; *P* = 0.015), were associated with shorter survival of GC. In addition, receiving palliative surgery increased risk (HR 2.55, 95% CI: 1.40--4.64; *P* = 0.002) while receiving postsurgery chemotherapy (HR 0.69, 95% CI: 0.50--0.96; *P* = 0.029) decreased risk of death ([Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

In the present study, we explored the associations of five SNPs of*DNMT1* gene (rs16999593, rs10420321, rs2288349, rs2228611, and rs2228612) with postoperational survival in Chinese gastric cancer patients. We found that rs2228611 was an independent prognostic factor where A allele of rs2228611 was associated with a 33% decreased risk of death (HR 0.67, 95% CI 0.49--0.91, *P* = 0.010, [Table 4](#tab4){ref-type="table"}).

To the best of our knowledge, this is the first study to evaluate the prognosis value of*DNMT1* SNPs on cancer. Previous studies mainly focused on the role in tumorigenesis and they reported controversial results. Khatami et al. first assessed the associations of SNPs of*DNMT1* with sporadic colorectal cancer in 208 cases and 213 controls in Iranian population and they observed no significant correlation \[[@B30]\]. Liu et al. expanded the sample size (1609 colon cancer cases and 1974 controls) and found that rs2228612 together with dietary factors (folate, methionine, vitamin B2, and vitamin B12 intake) could modify risk of colon cancer \[[@B31]\]. Similar controversial results were reported in breast cancer \[[@B21], [@B32]--[@B34]\]. In gastric cancer, Khatami et al. did not find any association between SNPs of*DNMT1* (rs2228611, rs721186, rs11488, and rs13784) and disease risk in Iranian patients \[[@B22]\]. Yang et al. examined this association in the Southern Chinese population and found that the C allele of rs16999593 increased the GC risk by 45% (OR 1.45, 95% CI: 1.00--2.11, *P* = 0.05). Our previous study, however, found that rs2228612 CC genotype increased the risk of precancerous disease (gastric atrophy) but not GC \[[@B24]\]. In the present study, we assessed their roles in the prognosis of GC and observed that A allele of rs2228611 was associated with favorable postoperational survival (HR 0.67, *P* = 0.010).

Methylation of CpG islands in promoter region can lead to transcriptional silence of genes. Silencing genes related to tumor suppressors or invasion suppressors promote tumorigenesis and metastasis \[[@B35]--[@B37]\]. DNMT1 is a key enzyme to maintain DNA methylation pattern \[[@B11]\]. Upregulation of DNMT1 downexpresses genes such as P53, P21 via increasing methylation, which could enhance proliferation of cancer cells \[[@B38]\]. Inhibition of DNMT1 restores expression of tumor suppression-related genes such as p16 and RGS10 and contributes to reduced cancer cell viability, decreased invasive capability, and enhanced treatment sensitivity \[[@B15], [@B16], [@B19], [@B39]\]. Aberrant expression of DNMT1 is associated with unfavorable prognosis of various cancers including GC \[[@B16]\]. Evaluating the prognostic value of genetic variations in*DNMT1* in the prognosis of cancer makes sense. In our study, we found that the minor allele A of rs2228611 was associated with longer life-span of postoperational GC patients.

Rs2228611 is located in exon 17 of*DNMT1* and the G-to-A change mediates a synonymous variation (CCG→CCA, Proline→Proline). Bioinformatics tool SNPinfo predicts that rs2228611 is in the region of exonic splicing enhancer (ESE) \[[@B40]\]. The G-to-A variation may alter the binding activity to serine/arginine-rich (SR) protein, change pre-RNA splicing of*DNMT1*, and therefore lead to alteration of normal DNMT1 expression. However, the exact mechanism of rs2228611 contributing to the prognosis of GC is still unknown and needs further investigation.

Two limitations should be noted in our study. The first one was that we did not clarify the underlying specific function of rs2228611 in the prognosis of GC due to our study design. The second one was that the follow-up time was relatively short as 50.5% of the patients are alive and the right side of the survival plot was censored, although the median follow-up time was 54.5 months. Therefore, more studies with larger-scale and longer follow-up time are needed to confirm our finding and to clarify the exact mechanism.

5. Conclusions {#sec5}
==============

In summary, our study provides the first evidence that polymorphisms of the*DNMT1* gene could modify the postoperational survival of gastric cancer cases. The A allele of rs2228611 contributes to favorable prognosis and has potentiality to serve as a prognostic predicting biomarker for gastric cancer.
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###### 

Characteristics and clinical features of gastric cancer patients.

  Variables                     Number of patients   Number of deaths   Mean OS (months)   Log-rank *P*             HR (95% CI)
  ----------------------------- -------------------- ------------------ ------------------ ------------------------ -------------
  All                           422                  195                54.5                                         
  Gender                                                                                                             
   Female                       117 (27.7)           45                 57.8               0.044                    1.00
   Male                         305 (72.3)           152                48.8               **1.41 (1.01--1.96)**    
  Age                                                                                                                
   ≤60                          209 (49.5)           91                 52.5               0.218                    1.00
   \>60                         213 (50.5)           106                50.2               1.19 (0.90--1.58)        
  Tumor size                                                                                                         
   ≤5 cm                        231 (55.8)           75                 62.6               \<0.001                  1.00
   \>5 cm                       183 (44.2)           116                39.5               **2.63 (1.96--3.52)**    
  Pathological type                                                                                                  
   Tubular adenocarcinoma       368 (87.4)           170                52.2               0.167                    1.00
   Signet ring cell carcinoma   22 (5.2)             8                  49.1               0.75 (0.37--1.53)        
   Others                       31 (7.4)             19                 38.8               1.49 (0.93--2.40)        
  Differentiation                                                                                                    
   Well to moderate             155 (37.1)           70                 55.7               0.161                    1.00
   Poor                         263 (62.9)           124                49.4               1.23 (0.92--1.65)        
  Depth of invasion                                                                                                  
   T1/T2                        97 (23.0)            13                 74.2               \<0.001                  1.00
   T3/T4                        322 (77.0)           182                44.8               **5.96 (3.39--10.46)**   
  Lymph metastasis                                                                                                   
   N0                           119 (29.1)           15                 75.5               \<0.001                  1.00
   N1/N2/N3                     300 (70.9)           180                42.0               **7.16 (4.22--12.14)**   
  Distant metastasis                                                                                                 
   M0                           392 (92.9)           174                53.9               \<0.001                  1.00
   M1                           30 (7.1)             23                 25.4               **2.70 (1.75--4.18)**    
  TNM stage                                                                                                          
   I/II                         240 (56.9)           57                 69.5               \<0.001                  1.00
   III/IV                       182 (43.1)           140                28.6               **5.97 (4.37--8.16)**    
  Lymph-vascular invasion                                                                                            
   Absent                       112 (26.5)           20                 73.4               \<0.001                  1.00
   Present                      305 (73.5)           173                43.9               **4.39 (2.76--6.99)**    
  Neural invasion                                                                                                    
   Absent                       199 (47.2)           65                 63.0               \<0.001                  1.00
   Present                      218 (52.8)           128                42.4               **2.42 (1.80--3.27)**    
  Radical surgery                                                                                                    
   Yes                          407 (96.4)           182                53.6               \<0.001                  1.00
   No^a^                        15 (3.6)             15                 10.8               **5.61 (3.28--9.60)**    
  Chemotherapy^b^                                                                                                    
   None                         284 (67.3)           132                51.7               0.157                    1.00
   XELOX                        29 (6.9)             9                  62.8               0.55 (0.28--1.08)        
   FOLFOX-4                     77 (18.2)            36                 51.3               0.98 (0.68--1.41)        
   Others                       32 (7.6)             20                 39.6               1.34 (0.84--2.15)        

OS: overall survival; HR: hazard ratio; CI: confidence interval.

^a^Fifteen patients received palliative surgery.

^b^XELOX (capecitabine and oxaliplatin); FOLFOX-4 (5-fluorouracil, leucovorin, and oxaliplatin); other chemotherapies included 5-fluorouracil; Xeloda alone; paclitaxel plus leucovorin and tegafurum; LV5-FU2 (leucovorin plus 5-fluorouracil); and FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin).

###### 

Associations between the SNPs and clinical parameters of gastric cancer patients.

                                rs10420321   *P*    rs16999593   *P*    rs2228612   *P*     rs2228611   *P*    rs2288349   *P*                                 
  ----------------------------- ------------ ------ ------------ ------ ----------- ------- ----------- ------ ----------- ------ ------ ------- ------ ------ -------
  *N*                           130          257                 268    154                 137         285                221    199            237    182     
  Gender                                                                                                                                                        
   Male                         31.9         68.1   0.334        62.4   37.6        0.532   31.4        68.6   0.650       53.3   46.7   0.885   55.2   44.8   0.538
   Female                       36.9         63.1                65.6   34.4                33.6        66.4               54.0   46.0           58.4   41.6    
  Age                                                                                                                                                           
   ≤60                          34.5         65.5   0.600        64.7   35.3        0.571   34.0        66.0   0.392       54.0   46.0   0.837   52.6   47.4   0.154
   \>60                         32.0         68.0                62.1   37.9                30.2        69.8               53.0   47.0           59.3   40.7    
  Tumor size                                                                                                                                                    
   ≤5 cm                        33.6         66.4   0.982        64.8   35.2        0.668   33.1        66.9   0.807       50.6   49.4   0.400   57.0   43.0   0.933
   \>5 cm                       33.5         66.5                62.8   37.2                31.9        68.1               54.7   45.3           56.6   43.4    
  Pathological type                                                                                                                                             
   Tubular adenocarcinoma       32.2         67.8   0.393        62.8   37.2        0.889   31.3        68.7   0.414       54.6   45.4   0.507   55.6   44.4   0.853
   Signet ring cell carcinoma   36.8         63.2                65.2   34.8                30.4        69.6               47.8   52.2           56.5   43.5    
   Others                       43.8         56.3                66.7   33.3                42.4        57.6               45.5   54.5           60.6   39.4    
  Differentiation                                                                                                                                               
   Well to moderate             37.6         62.4   0.191        61.1   38.9        0.501   34.4        65.6   0.458       57.7   42.3   0.152   54.5   45.5   0.646
   Poor                         31.1         68.9                64.4   35.6                30.9        69.1               50.5   49.5           56.8   43.2    
  TNM stage                                                                                                                                                     
   I/II                         29.6         70.4   0.065        62.9   37.1        0.710   29.4        70.6   0.183       52.0   48.0   0.618   58.5   41.5   0.354
   III/IV                       38.4         61.6                64.6   35.4                35.4        64.6               54.4   45.6           54.1   45.9    
  Lymph-vascular invasion                                                                                                                                       
   Absent                       33.0         67.0   0.849        60.7   39.3        0.499   31.6        68.4   0.800       49.6   50.4   0.446   57.8   42.2   0.829
   Present                      34.0         66.0                64.2   35.8                32.9        67.1               53.7   46.3           56.6   43.4    
  Neural invasion                                                                                                                                               
   Absent                       32.8         67.2   0.699        62.6   37.4        0.794   33.0        67.0   0.848       50.0   50.0   0.305   60.0   40.0   0.215
   Present                      34.7         65.3                63.8   36.2                32.1        67.9               55.0   45.0           54.1   45.9    
  Radical surgery                                                                                                                                               
   Yes                          33.2         66.8   0.995        63.7   36.3        0.415   31.9        68.1   0.910       53.5   46.5   0.991   56.2   43.8   0.827
   No                           33.3         66.7                53.3   46.7                33.3        66.7               53.3   46.7           53.3   46.7    
  Chemotherapy                                                                                                                                                  
   No                           30.2         69.8   0.056        59.9   40.1        0.028   28.7        71.3   0.026       56.4   43.6   0.069   55.1   44.9   0.530
   Yes                          39.8         60.2                70.7   29.3                39.3        60.7               47.1   52.9           58.3   41.7    

###### 

Associations between the SNPs and overall survival of gastric cancer patients.

  Genotypes    Overall patients *N* = 422   Mean OS   HR (95% CI)   *P*                     Adjusted HR (95% CI)^a^   Adjusted *P*            
  ------------ ---------------------------- --------- ------------- ----------------------- ------------------------- ----------------------- -----------
  rs10420321                                                                                                                                   
   AA          130 (33.6)                   62        50.0          1.00                                              1.00                     
   AG          189 (48.8)                   85        53.6          0.90 (0.65--1.24)       0.510                     0.91 (0.65--1.26)       0.553
   GG          68 (17.6)                    32        52.1          0.97 (0.63--1.49)       0.890                     0.98 (0.64--1.50)       0.917
  Dominant                                                                                                                                     
   AA          130 (33.6)                   62        50.0          1.00                                              1.00                     
   AG/GG       257 (66.4)                   117       53.3          0.90 (0.67--1.24)       0.490                     0.92 (0.68--1.26)       0.618
  Recessive                                                                                                                                    
   AA/AG       319 (82.4)                   147       52.4          1.00                                              1.00                     
   GG          68 (17.6)                    32        52.1          1.04 (0.71--1.52)       0.730                     1.04 (0.70--1.52)       0.857
  rs16999593                                                                                                                                   
   TT          268 (63.5)                   127       51.3          1.00                                              1.00                     
   TC          135 (32.0)                   63        52.3          0.98 (0.72--1.32)       0.891                     0.99 (0.73--1.34)       0.986
   CC          19 (4.5)                     7         50.5          0.80 (0.37--1.70)       0.555                     0.80 (0.37--1.72)       0.802
  Dominant                                                                                                                                     
   TT          268 (63.5)                   127       51.3          1.00                                              1.00                     
   TC/CC       154 (36.5)                   70        52.9          0.96 (0.72--1.28)       0.767                     0.96 (0.72--1.29)       0.801
  Recessive                                                                                                                                    
   TT/TC       403 (95.5)                   190       51.8          1.00                                              1.00                     
   CC          19 (4.5)                     7         50.5          0.80 (0.38--1.70)       0.471                     0.81 (0.38--1.72)       0.576
  rs2228612                                                                                                                                    
   TT          137 (32.4)                   65        50.1          1.00                                              1.00                     
   TC          197 (46.7)                   90        52.9          0.92 (0.67--1.27)       0.629                     0.92 (0.67--1.27)       0.614
   CC          88 (20.9)                    42        51.3          1.00 (0.68--1.47)       1.000                     1.03 (0.70--1.53)       0.864
  Dominant                                                                                                                                     
   TT          137 (32.4)                   65        50.1          1.00                                              1.00                     
   TC/CC       285 (67.6)                   132       52.5          0.95 (0.70--1.27)       0.720                     0.96 (0.71--1.29)       0.760
  Recessive                                                                                                                                    
   TT/TC       334 (79.1)                   155       52.0          1.00                                              1.00                     
   CC          88 (20.9)                    42        51.3          1.05 (0.75--1.47)       0.790                     1.09 (0.77--1.53)       0.638
  rs2228611                                                                                                                                    
   GG          221 (52.6)                   117       47.8          1.00                                              1.00                     
   GA          169 (40.3)                   66        57.5          **0.66 (0.48--0.89)**   **0.006**                 **0.65 (0.48--0.88)**   **0.006**
   AA          30 (7.1)                     13        45.9          0.81 (0.46--1.44)       0.469                     0.80 (0.45--1.42)       0.444
  Dominant                                                                                                                                     
   GG          221 (52.6)                   117       47.8          1.00                                              1.00                     
   GA/AA       199 (47.4)                   79        56.7          **0.68 (0.51--0.90)**   **0.007**                 **0.67 (0.51--0.90)**   **0.007**
  Recessive                                                                                                                                    
   GG/GA       390 (92.9)                   183       52.1          1.00                                              1.00                     
   AA          30 (7.1)                     13        45.9          0.96 (0.55--1.69)       0.894                     0.95 (0.54--1.68)       0.860
  rs2288349                                                                                                                                    
   GG          237 (56.6)                   102       54.7          1.00                                              1.00                     
   GA          151 (36.0)                   77        47.4          1.27 (0.95--1.71)       0.1105                    1.26 (0.94--1.70)       0.128
   AA          31 (7.4)                     17        46.0          1.39 (0.84--2.33)       0.204                     1.37 (0.82--2.30)       0.228
  Dominant                                                                                                                                     
   GG          237 (56.6)                   102       54.7          1.00                                              1.00                     
   GA/AA       182 (43.4)                   94        47.7          1.29 (0.98--1.71)       0.072                     1.28 (0.97--1.70)       0.086
  Recessive                                                                                                                                    
   GG/GA       388 (92.6)                   179       52.4          1.00                                              1.00                     
   AA          31 (7.4)                     17        46.0          1.27 (0.77--2.08)       0.353                     1.25 (0.76--2.06)       0.376

OS: overall survival; HR: hazard ratio; CI: confidence interval.

^a^Adjusted for age, sex, TNM stage, and postoperational chemotherapy.

###### 

Multivariate Cox regression analysis on the survival of GC.

  Variables                                             HR     95% CI       *P*
  ----------------------------------------------------- ------ ------------ ---------
  rs2228611 (GA/AA versus GG)                           0.67   0.49--0.91   0.010
  Sex (male versus female)                              1.80   1.22--2.67   0.003
  TNM stages (III + IV versus I + II)                   4.76   3.28--6.90   \<0.001
  Tumor sizes (≥5 cm versus \<5 cm)                     1.56   1.13--2.16   0.007
  Lymph-vascular invasion (present versus absent)       1.52   1.08--2.14   0.015
  Surgical method (palliative versus radical surgery)   2.55   1.40--4.64   0.002
  Chemotherapy (yes versus no)                          0.69   0.50--0.96   0.029

HR: hazard ratio; CI: confidence interval.

[^1]: Academic Editor: Gad Rennert
